InMed Pharmaceuticals Inc. (C:IN)
Business Focus: Bio Therapeutic Drugs
May 06, 2021 07:30 am ET
InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), will report financial...
May 04, 2021 07:30 am ET
InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric....
Apr 28, 2021 07:30 am ET
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a world leader in the clinical development of cannabinol (“CBN”), today announced that it has filed Clinical Trial Applications (“CTAs”) in Austria, Israel and Serbia as...
Apr 27, 2021 07:30 am ET
InMed Pharmaceuticals Announces Voluntary Delisting from TSX
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that,...
Apr 26, 2021 07:30 am ET
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that its...
Mar 03, 2021 06:00 pm ET
InMed to Present at Virtual Conferences in March 2021
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unmet medical need and leading the clinical development...
Feb 16, 2021 06:30 am ET
InMed Announces Closing of US$4.5 Million Private Placement
VANCOUVER, BC, Feb. 16, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has closed the previously announced private placement.
Feb 16, 2021 06:30 am ET
InMed Announces Closing of US$4.5 Million Private Placement
VANCOUVER, BC, Feb. 16, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has closed the previously announced private placement.
Feb 11, 2021 06:30 am ET
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
VANCOUVER, BC, Feb. 11, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the second quarter of fiscal year 2021 ("2Q21") which ended December 31, 2020.
Feb 11, 2021 06:30 am ET
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
VANCOUVER, BC, Feb. 11, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the second quarter of fiscal year 2021 ("2Q21") which ended December 31, 2020.
Feb 05, 2021 08:00 pm ET
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results
VANCOUVER, BC, Feb. 5, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), will report financial results for the second quarter of fiscal year 2021 ending December 31, 2020, on Thursday, February 11, 2021.
Feb 05, 2021 08:00 pm ET
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results
VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), will report financial results for the second quarter of fiscal year 2021 ending December 31, 2020, on Thursday, February 11, 2021.
Feb 05, 2021 08:53 am ET
IIROC Trade Resumption - IN
TORONTO, Feb. 5, 2021 /CNW/ - Trading resumes in:
Feb 05, 2021 08:37 am ET
IIROC Trading Halt - IN
TORONTO, Feb. 5, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 05, 2021 08:34 am ET
InMed Announces US$4.5 Million Private Placement
VANCOUVER, BC, Feb. 5, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced today announced that it has entered into definitive agreements with certain institutional investors to raise aggregate gross proceeds of approximately US$4.5 million at a price of US$4.25 per unit in a private placement of its equity securities. Each unit consists of one common share and 0.66 of
Feb 05, 2021 08:34 am ET
InMed Announces US$4.5 Million Private Placement
VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced today announced that it has entered into definitive agreements with certain institutional investors to raise aggregate gross proceeds of approximately US$4.5 million at a price of US$4.25 per unit in a private placement of its equity securities. Each unit consists of one common share and 0
Jan 19, 2021 01:00 pm ET
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
InMed's Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers
Jan 19, 2021 01:00 pm ET
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
InMed's Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers
Jan 08, 2021 06:30 am ET
Jan 08, 2021 06:30 am ET
Jan 05, 2021 03:52 pm ET
InMed to Participate at Virtual Conferences in January 2021
VANCOUVER, BC, Jan. 5, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that InMed will be participating in the following virtual investor and partnering conferences in January 2021.
Jan 05, 2021 03:52 pm ET
InMed to Participate at Virtual Conferences in January 2021
VANCOUVER, BC, Jan. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that InMed will be participating in the following virtual investor and partnering conferences in January 2021.
Dec 03, 2020 06:30 am ET
Dec 03, 2020 06:30 am ET
Nov 25, 2020 06:30 am ET
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, BC, Nov. 25, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-101-HV Phase 1 clinical trial ("Study 101").
Nov 25, 2020 06:30 am ET
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-101-HV Phase 1 clinical trial ("Study 101").
Nov 24, 2020 07:00 pm ET
InMed Announces Election of Directors
VANCOUVER, BC, Nov. 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today confirmed that, at its annual general and special meeting of shareholders held on November 20, 2020 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 7, 202
Nov 24, 2020 07:00 pm ET
InMed Announces Election of Directors
VANCOUVER, BC, Nov. 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today confirmed that, at its annual general and special meeting of shareholders held on November 20, 2020 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October
Nov 18, 2020 06:30 am ET
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
VANCOUVER, BC, Nov. 18, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), and BayMedica Inc., a company specializing in the design and manufacture of rare natural cannabinoids and cannabinoid analogs through biosynthesis and pharmaceutical chemistry, announced today they have entered into a broad reciprocal research collaboration to explore synergies between technologies ow
Nov 18, 2020 06:30 am ET
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
VANCOUVER, BC, Nov. 18, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), and BayMedica Inc., a company specializing in the design and manufacture of rare natural cannabinoids and cannabinoid analogs through biosynthesis and pharmaceutical chemistry, announced today they have entered into a broad reciprocal research collaboration to explore synergies between technolo
Nov 16, 2020 10:42 am ET
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
VANCOUVER, BC, Nov. 16, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (CBN), today announced that it has closed the previously announced public offering of common shares, together with accompanying warrants.
Nov 16, 2020 10:42 am ET
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
VANCOUVER, BC, Nov. 16, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (CBN), today announced that it has closed the previously announced public offering of common shares, together with accompanying warrants.
Nov 13, 2020 06:30 am ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
VANCOUVER, BC, Nov. 13, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), in compliance with continuous disclosure obligations in Canada, today reported financial results for the first quarter of fiscal year 2021 ("1Q21") which ended September 30, 2020.
Nov 13, 2020 06:30 am ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
VANCOUVER, BC, Nov. 13, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), in compliance with continuous disclosure obligations in Canada, today reported financial results for the first quarter of fiscal year 2021 ("1Q21") which ended September 30, 2020.
Nov 12, 2020 08:19 am ET
IIROC Trade Resumption - IN
TORONTO, Nov. 12, 2020 /CNW/ - Trading resumes in:
Nov 12, 2020 08:10 am ET
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
VANCOUVER, BC, Nov. 12, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has priced a public offering of an aggregate of 1,780,000 common shares, together with accompanying warrants to purchase up to an aggregate of 1,780,000 common shares, at a public offering price of US$4.50 per share and accompanying warrant. Each common share will be sold in the offerin
Nov 12, 2020 08:10 am ET
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
VANCOUVER, BC, Nov. 12, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that it has priced a public offering of an aggregate of 1,780,000 common shares, together with accompanying warrants to purchase up to an aggregate of 1,780,000 common shares, at a public offering price of US$4.50 per share and accompanying warrant. Each common share will be sold in the
Nov 12, 2020 08:09 am ET
IIROC Trading Halt - IN
TORONTO, Nov. 12, 2020 /CNW/ - The following issues have been halted by IIROC:
Nov 05, 2020 05:21 pm ET
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020
VANCOUVER, BC, Nov. 5, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that, due to the regulatory quiet period the Company is in, it has rescheduled the reporting of its financial results for the first quarter of fiscal year 2021, ending September 30, 2020. Originally scheduled to take place on Friday, November 6, 2020, the reporting, and corresponding conference
Nov 05, 2020 05:21 pm ET
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020
VANCOUVER, BC, Nov. 5, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that, due to the regulatory quiet period the Company is in, it has rescheduled the reporting of its financial results for the first quarter of fiscal year 2021, ending September 30, 2020. Originally scheduled to take place on Friday, November 6, 2020, the reporting, and corresponding con
Nov 04, 2020 06:30 am ET
Nov 04, 2020 06:30 am ET
Sep 24, 2020 07:30 am ET
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, BC, Sept. 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its second Phase 1 clinical trial with INM-755 have completed treatment. INM-755 is being developed as a topical CBN-based cream to potentially treat Epidermolysis Bullosa ("EB") as well as potentially other dermatological diseases.
Sep 22, 2020 07:30 am ET
InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing
TSX:IN OTCQX:IMLFF
Sep 08, 2020 07:30 am ET
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update
VANCOUVER, BC, Sept. 8, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the fiscal year ended June 30, 2020.
Sep 02, 2020 07:30 am ET
Jul 07, 2020 07:30 am ET
InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755
TSX:IN OTCQX:IMLFF
Jul 07, 2020 07:30 am ET
InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755
TSX:IN OTCQX:IMLFF
Jun 30, 2020 06:18 pm ET
InMed Announces Completion of Share Consolidation
Trading of Consolidated Shares on TSX Expected to Begin on July 3rd, 2020
Jun 30, 2020 06:18 pm ET
InMed Announces Completion of Share Consolidation
Trading of Consolidated Shares on TSX Expected to Begin on July 3rd, 2020
Jun 24, 2020 07:30 am ET
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System
VANCOUVER, BC, June 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today introduced details of IntegraSynTM, the Company's new approach to producing pharmaceutical-grade cannabinoids. IntegraSynTM is a manufacturing system that integrates biosynthesis with other traditional drug manufacturing methods with the goal of improving production of low-cost, high quality
Jun 24, 2020 07:30 am ET
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System
VANCOUVER, BC, June 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today introduced details of IntegraSynTM, the Company's new approach to producing pharmaceutical-grade cannabinoids. IntegraSynTM is a manufacturing system that integrates biosynthesis with other traditional drug manufacturing methods with the goal of improving production of low-cost, high q
Jun 19, 2020 06:20 pm ET
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
VANCOUVER, BC, June 19, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission ("SEC") in connection with a proposed offering of up to US$12 million of common shares (the "Offering"). In connection with the proposed Offering, InMed has also applied
Jun 19, 2020 06:20 pm ET
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
VANCOUVER, BC, June 19, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission ("SEC") in connection with a proposed offering of up to US$12 million of common shares (the "Offering"). In connection with the proposed Offering, InMed has also a
May 27, 2020 07:30 am ET
InMed Releases CBN Preclinical Results in Glaucoma
VANCOUVER, May 27, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today provided an update on the preclinical results from its INM-088 drug development program that indicate a potential neuroprotective effect of cannabinol ("CBN") on nerve cells located in the eye. INM-088 is being developed as a potential treatment option for ocular diseases, such as glaucoma, where neu
May 27, 2020 07:30 am ET
InMed Releases CBN Preclinical Results in Glaucoma
VANCOUVER, May 27, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today provided an update on the preclinical results from its INM-088 drug development program that indicate a potential neuroprotective effect of cannabinol ("CBN") on nerve cells located in the eye. INM-088 is being developed as a potential treatment option for ocular diseases, such as glaucoma, wh
May 19, 2020 07:30 am ET
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family
VANCOUVER, May 19, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a key Patent Cooperation Treaty ("PCT") patent application directed to the Company's biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids.
May 19, 2020 07:30 am ET
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family
VANCOUVER, May 19, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a key Patent Cooperation Treaty ("PCT") patent application directed to the Company's biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids.
May 14, 2020 07:30 am ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
VANCOUVER, May 14, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the third quarter of fiscal year 2020 ("3Q20") which ended March 31, 2020.
May 14, 2020 07:30 am ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
VANCOUVER, May 14, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the third quarter of fiscal year 2020 ("3Q20") which ended March 31, 2020.
May 12, 2020 07:30 am ET
InMed Files PCT Patent Application for Neuroprotection in Glaucoma
VANCOUVER, May 12, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the potential of cannabinoids in the prevention of neuron damage associated with glaucoma.
May 12, 2020 07:30 am ET
InMed Files PCT Patent Application for Neuroprotection in Glaucoma
VANCOUVER, May 12, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the potential of cannabinoids in the prevention of neuron damage associated with glaucoma.
May 08, 2020 07:30 am ET
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020
VANCOUVER, May 8, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year 2020 ending March 31, 2020 (3Q20), on Thursday, May 14, 2020.
May 08, 2020 07:30 am ET
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020
VANCOUVER, May 8, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year 2020 ending March 31, 2020 (3Q20), on Thursday, May 14, 2020.
May 07, 2020 07:30 am ET
InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference
VANCOUVER, May 7, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), announced that Eric. A. Adams, President & CEO of InMed, will present a corporate overview as part of the upcoming virtual conference:
May 07, 2020 07:30 am ET
InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference
VANCOUVER, May 7, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), announced that Eric. A. Adams, President & CEO of InMed, will present a corporate overview as part of the upcoming virtual conference:
May 05, 2020 07:30 am ET
InMed and Almac Group Developing Improved Cannabinoid Production Methods
VANCOUVER, May 5, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it is working with the Almac Group (UK) ("Almac") on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.
May 05, 2020 07:30 am ET
InMed and Almac Group Developing Improved Cannabinoid Production Methods
VANCOUVER, May 5, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it is working with the Almac Group (UK) ("Almac") on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.
Apr 30, 2020 07:30 am ET
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
VANCOUVER, April 30, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced it has received regulatory and ethics board approval of its Clinical Trial Application ("CTA") to conduct its second Phase 1 trial with INM-755.
Apr 30, 2020 07:30 am ET
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
VANCOUVER, April 30, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced it has received regulatory and ethics board approval of its Clinical Trial Application ("CTA") to conduct its second Phase 1 trial with INM-755.
Apr 01, 2020 07:30 am ET
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, April 1, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its 755-101-HV Phase 1 clinical trial have completed treatment and clinical evaluation.
Apr 01, 2020 07:30 am ET
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, April 1, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its 755-101-HV Phase 1 clinical trial have completed treatment and clinical evaluation.
Mar 24, 2020 07:30 am ET
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
VANCOUVER, March 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a second Phase 1 human clinical trial for INM-755 in healthy volunteers.
Mar 24, 2020 07:30 am ET
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
VANCOUVER, March 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a second Phase 1 human clinical trial for INM-755 in healthy volunteers.
Mar 20, 2020 07:30 am ET
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
VANCOUVER, March 20, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today provided an update on the impact of the global outbreak of COVID-19 on its business operations.
Mar 20, 2020 07:30 am ET
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
VANCOUVER, March 20, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today provided an update on the impact of the global outbreak of COVID-19 on its business operations.
Mar 10, 2020 01:24 pm ET
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, March 10, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
Feb 20, 2020 09:15 am ET
Edison issues update on InMed Pharmaceuticals (IN)
LONDON, UK / ACCESSWIRE / February 20, 2020 / InMed Pharmaceuticals (TSX:IN) recently announced that the first human clinical trial (755-101-HV) of its lead program, INM-755 for the treatment of epidermolysis bullosa (EB), is currently around 50% enrolled with full enrollment expected this quarter and data in H220. This trial is testing two strengths of INM-755 cream on the intact skin of 22 healthy volunteers. The company expects to file a clinical trial application (CTA) for a second trial (755-102-HV) this quarter with initiation in Q220. This upcoming trial would test INM-
Feb 14, 2020 06:30 am ET
InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
- Commenced Dosing of Patients in Phase 1 Clinical Trial with INM-755 -
Feb 07, 2020 06:30 am ET
InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020
VANCOUVER, Feb. 7, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the second quarter of fiscal year 2020 ending December 31, 2019 ("2Q20"), on Friday, February 14, 2020.
Jan 21, 2020 06:30 am ET
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview
VANCOUVER, Jan. 21, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today published additional information describing in detail its leading cannabinol-based therapeutics programs on its corporate website at www.inmedpharma.com.
Jan 20, 2020 06:30 am ET
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials
VANCOUVER, Jan. 20, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, today revealed the rare cannabinoid cannabinol ("CBN") as the active pharmaceutical ingredient ("API") in its two product candidates under development: INM-755 for epidermolysis bullosa ("EB") and INM-088 for glaucoma. InMed is leading the way in the clinical development of CBN to treat human disease.
Jan 16, 2020 06:30 am ET
InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress
VANCOUVER, Jan. 16, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that members of its senior scientific and clinical team will be attending the EB2020 World Congress, organized and funded by the Dystrophic Epidermolysis Bullosa Research Association (DEBRA), from January 19-23, 2020 in London, UK.
Jan 10, 2020 04:56 pm ET
InMed Announces Election of Directors
VANCOUVER, Jan. 10, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today confirmed that at its annual general meeting of shareholders held on December 19, 2019 (the "Meeting"), all directors nominated as listed in the information circular dated November 7, 2019 were elected as directors of the Company for the ensuing year. InMed filed a report of voting results on SEDAR at www.sedar.com on December 20, 2019.
Jan 08, 2020 06:30 am ET
InMed Pharmaceuticals to Present at the Biotech Showcase Conference
VANCOUVER, Jan. 8, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President & CEO will be presenting at the Biotech Showcase conference to be held at the Hilton San Francisco Union Square in San Francisco, California from January 13-15, 2020.
Dec 09, 2019 06:30 am ET
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa
VANCOUVER, Dec. 9, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received regulatory and ethics board approval of its Clinical Trial Application ("CTA") to conduct a Phase 1 trial in the Netherlands for INM-755, a cannabinoid-based topical cream. The Company intends to initiate subject recruitment immediately.
Nov 18, 2019 08:45 am ET
Edison issues update on InMed Pharmaceuticals
LONDON, UK / ACCESSWIRE / November 18, 2019 / InMed Pharmaceuticals (TSX:IN) recently announced that it filed a Clinical Trial Application in the Netherlands for INM-755, which is being developed for epidermolysis bullosa. Approval of the CTA is expected around the end of November with the first trial (755-101-HV) expected to begin in December. This trial will test two strengths of INM-755 cream on the intact skin of 22 healthy volunteers. Following the completion of this trial, the company expects to initiate trial 755-102-HV, which would test INM-755 on eight healthy volunte
Nov 11, 2019 07:30 am ET
InMed Pharmaceuticals to Present at the Cowen Conference
VANCOUVER, Nov. 11, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric Hsu, Senior Vice President, Preclinical Research and Development, will be participating at Cowen 2nd Annual Boston Cannabis Conference being held on November 12th and 13th, 2019, at the InterContinental Boston.
Nov 11, 2019 07:30 am ET
InMed Pharmaceuticals to Present at the Cowen Conference
VANCOUVER, Nov. 11, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric Hsu, Senior Vice President, Preclinical Research and Development, will be participating at Cowen 2nd Annual Boston Cannabis Conference being held on November 12th and 13th, 2019, at the InterContinental Boston.
Nov 08, 2019 06:30 am ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
VANCOUVER, Nov. 8, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20").
Nov 08, 2019 06:30 am ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
VANCOUVER, Nov. 8, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20").
Nov 05, 2019 06:30 am ET
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial
VANCOUVER, Nov. 5, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers.
Nov 05, 2019 06:30 am ET
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial
VANCOUVER, Nov. 5, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers.
Nov 04, 2019 06:30 am ET
InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019
VANCOUVER, Nov. 4, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20"), on Friday, November 8, 2019.
Nov 04, 2019 06:30 am ET
InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019
VANCOUVER, Nov. 4, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20"), on Friday, November 8, 2019.
Oct 18, 2019 12:25 pm ET
InMed Pharmaceuticals to Present at the BIO Investor Forum
VANCOUVER, Oct. 18, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the BIO Investor Forum in San Francisco:
Oct 18, 2019 12:25 pm ET
InMed Pharmaceuticals to Present at the BIO Investor Forum
VANCOUVER, Oct. 18, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the BIO Investor Forum in San Francisco:
Sep 26, 2019 07:35 am ET
Edison Issues Update on InMed Pharmaceuticals (IN)
LONDON, UK / ACCESSWIRE / September 26, 2019 / InMed (IN) recently reported results for FY19 and is on track for INM-755 for epidermolysis bullosa (EB) to be in the clinic by the end of 2019. The Phase I programme will consist of two trials, one in healthy volunteers with intact skin and the other in healthy volunteers with small wounds. A Phase I/II trial in EB patients is expected to begin in Q121. In glaucoma, the company has switched its lead candidate to INM-088, which has some specific advantages to the former lead, INM-085. Advanced preclinical and formulation developme
Sep 23, 2019 11:00 am ET
InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society's annual conference
VANCOUVER, Sept. 23, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Karen Long, InMed's Senior Director, Drug Development, will be presenting at the Regulatory Affairs Professionals Society's annual conference at the Philadelphia Convention Center in Philadelphia, 21-24 September 2019.
Sep 23, 2019 11:00 am ET
InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society's annual conference
VANCOUVER, Sept. 23, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Karen Long, InMed's Senior Director, Drug Development, will be presenting at the Regulatory Affairs Professionals Society's annual conference at the Philadelphia Convention Center in Philadelphia, 21-24 September 2019.
Sep 19, 2019 07:30 am ET
Sep 19, 2019 07:30 am ET
Sep 12, 2019 11:00 am ET
Sep 12, 2019 11:00 am ET
Sep 03, 2019 07:25 am ET
InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Martin Bott steps down from the Board of Directors
Sep 03, 2019 07:25 am ET
InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Martin Bott steps down from the Board of Directors
Aug 29, 2019 07:25 am ET
InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
InMed's Eric Hsu and Michael Woudenberg among Event's Expert Speakers
Aug 29, 2019 07:25 am ET
InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
InMed's Eric Hsu and Michael Woudenberg among Event's Expert Speakers
Aug 02, 2019 07:25 am ET
Aug 02, 2019 07:25 am ET
Jul 02, 2019 07:25 am ET
InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
TSX:INOTCQX:IMLFF
Jul 02, 2019 07:25 am ET
InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
TSX:INOTCQX:IMLFF
May 15, 2019 07:25 am ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
VANCOUVER, May 15, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2019, which is the Company's third quarter of fiscal year 2019 ("3Q19").
May 15, 2019 07:25 am ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
VANCOUVER, May 15, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2019, which is the Company's third quarter of fiscal year 2019 ("3Q19").
May 08, 2019 07:25 am ET
May 08, 2019 07:25 am ET
Mar 18, 2019 07:25 am ET
InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology
TSX: IN OTCQX: IMLFF
Mar 18, 2019 07:25 am ET
InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology
TSX: IN OTCQX: IMLFF
Mar 13, 2019 07:25 am ET
InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program
Transition to INM-755 Expected to Improve the Probability of Development and Regulatory Success
Mar 13, 2019 07:25 am ET
InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program
Transition to INM-755 Expected to Improve the Probability of Development and Regulatory Success
Mar 12, 2019 07:25 am ET
Mar 12, 2019 07:25 am ET
Mar 06, 2019 06:25 am ET
Mar 06, 2019 06:25 am ET
Feb 14, 2019 08:02 am ET
Edison issues update on InMed Pharmaceuticals (IN)
InMed (IN) recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis bullosa (EB) into the clinic by the end of the year. The company recently completed two topical seven-day dose-ranging studies in...
Feb 12, 2019 06:25 am ET
Feb 12, 2019 06:25 am ET
Feb 05, 2019 06:25 am ET
Feb 05, 2019 06:25 am ET
Jan 11, 2019 06:25 am ET
Jan 11, 2019 06:25 am ET
Jan 03, 2019 09:25 am ET
Jan 03, 2019 09:25 am ET
Dec 04, 2018 06:25 am ET
Dec 04, 2018 06:25 am ET
Nov 21, 2018 04:26 am ET
Edison issues update on InMed Pharmaceuticals (IN)
InMed recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa (EB) into the clinic by H219. So far, its selected formulation has demonstrated good drug penetration...
Nov 12, 2018 06:25 am ET
Nov 12, 2018 06:25 am ET
Nov 05, 2018 06:25 am ET
Nov 05, 2018 06:25 am ET
Nov 05, 2018 06:20 am ET
Nov 05, 2018 06:20 am ET
Nov 01, 2018 06:00 am ET
BTV Explores Tech Companies on Investors' Radar
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2018) - On BNN Sat Nov. 3 & Sun Nov. 4, 2018 - BTV- Business Television visits state-of-the-art technology companies ranging from social media to pharmaceuticals. Full Episode
Oct 10, 2018 07:25 am ET
InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018
TSX: IN OTCQX: IMLFF
Oct 10, 2018 07:25 am ET
InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018
TSX: IN OTCQX: IMLFF
Oct 03, 2018 07:25 am ET
Oct 03, 2018 07:25 am ET
Sep 25, 2018 07:25 am ET
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
VANCOUVER, Sept. 25, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the Company's INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Company's in
Sep 25, 2018 07:25 am ET
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
VANCOUVER, Sept. 25, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the Company's INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Compa
Sep 13, 2018 07:25 am ET
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
VANCOUVER, Sept. 13, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18").
Sep 13, 2018 07:25 am ET
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
VANCOUVER, Sept. 13, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18").
Sep 11, 2018 07:25 am ET
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
VANCOUVER, Sept. 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the biosynthe
Sep 11, 2018 07:25 am ET
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
VANCOUVER, Sept. 11, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the bi
Sep 10, 2018 07:25 am ET
Sep 10, 2018 07:25 am ET
Sep 07, 2018 07:25 am ET
InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
VANCOUVER, Sept. 7, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18"), on Thursday, September 13, 2018.
Sep 07, 2018 07:25 am ET
InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
VANCOUVER, Sept. 7, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18"), on Thursday, September 13, 2018.
Aug 31, 2018 07:25 am ET
Aug 31, 2018 07:25 am ET
Aug 01, 2018 07:25 am ET
InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
VANCOUVER, Aug. 1, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8th, 2018, at 8:30 AM EST at the InterContinental Boston.
Aug 01, 2018 07:25 am ET
InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
VANCOUVER, Aug. 1, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8th, 2018, at 8:30 AM EST at the InterContinental Boston.
Jun 21, 2018 11:13 am ET
InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 12, 2018 09:54 am ET
InMed Pharmaceuticals announces increase in Bought Deal offering to $13 million
InMed Pharmaceuticals Inc. (TSX:IN) (“InMed” or the “Company”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase, as underwriter, 14,444,560...
Jun 12, 2018 07:30 am ET
InMed Pharmaceuticals Announces $10 Million Bought Deal
InMed Pharmaceuticals Inc. (TSX:IN) (“InMed” or the “Company”) is pleased to announce that it has entered into a letter of engagement with Eight Capital, as underwriter, under which Eight Capital has agreed to purchase 11,111,200 units of the...
May 29, 2018 07:25 am ET
InMed to Present at the 8th Annual LD Micro Invitational Conference
VANCOUVER, May 29, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the 8th annual LD Micro Invitational conference on June 4th, 2018, at 2:00 PM PST at the Luxe Sunset Bel Air in Los Angeles, California.
May 29, 2018 07:25 am ET
InMed to Present at the 8th Annual LD Micro Invitational Conference
VANCOUVER, May 29, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the 8th annual LD Micro Invitational conference on June 4th, 2018, at 2:00 PM PST at the Luxe Sunset Bel Air in Los Angeles, California.
May 14, 2018 07:25 am ET
InMed Files Patent Application for INM-085 Glaucoma Program
VANCOUVER, May 14, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced it has filed a Patent Cooperation Treaty ("PCT") application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a priority
May 14, 2018 07:25 am ET
InMed Files Patent Application for INM-085 Glaucoma Program
VANCOUVER, May 14, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced it has filed a Patent Cooperation Treaty ("PCT") application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a pr
May 11, 2018 07:25 am ET
InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
VANCOUVER, May 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18").
May 11, 2018 07:25 am ET
InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
VANCOUVER, May 11, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18").
May 04, 2018 08:30 am ET
OTC Markets Group Welcomes InMed Pharmaceuticals Inc. to OTCQX
NEW YORK, May 4, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced InMed Pharmaceuticals Inc. (TSX: IN; OTCQX: IMLFF), a cannabinoid-focused biopharmaceutical company, has qualified to trade on the OTCQX® Best Market. InMed Pharmaceuticals upgraded to OTCQX from the OTCQB® Venture Market.
May 01, 2018 08:30 am ET
InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board
TSX:IN OTCQB:IMLFF
May 01, 2018 08:30 am ET
InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board
TSX:IN OTCQB:IMLFF
Apr 17, 2018 10:31 am ET
InMed Pharmaceuticals Inc. Opens the Market
TORONTO, April 17, 2018 /CNW/ - Eric Adams, President & CEO, InMed Pharmaceuticals Inc. (IN), joined Shaun McIver, Chief Client Officer, TMX Group, to open the market. InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed Pharmaceuticals Inc. commenced trading on Toronto Stock Exchange on March 26, 2018.
Apr 17, 2018 08:00 am ET
InMed Rings the Opening Bell at the Toronto Stock Exchange
VANCOUVER, April 17, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that the Company will ring the opening bell at the Toronto Stock Exchange ("TSX") today in honor of its migration to the exchange on March 26, 2018.
Apr 17, 2018 08:00 am ET
InMed Rings the Opening Bell at the Toronto Stock Exchange
VANCOUVER, April 17, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that the Company will ring the opening bell at the Toronto Stock Exchange ("TSX") today in honor of its migration to the exchange on March 26, 2018.
Apr 11, 2018 08:00 am ET
InMed Announces Appointment of Joshua Blacher as Chief Business Officer
TSX: INOTCQB: IMLFF
Apr 11, 2018 08:00 am ET
InMed Announces Appointment of Joshua Blacher as Chief Business Officer
TSX: INOTCQB: IMLFF
Mar 23, 2018 06:00 am ET
InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
Trading on the TSX will commence March 26, 2018
Mar 23, 2018 06:00 am ET
InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
Trading on the TSX will commence March 26, 2018
Mar 13, 2018 04:30 am ET
InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development
CSE: IN OTCQB: IMLFF
Mar 13, 2018 04:30 am ET
InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development
CSE: IN OTCQB: IMLFF
Mar 12, 2018 07:30 am ET
InMed to Present at 30th Annual ROTH Capital Conference
VANCOUVER, March 12, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California. InMed's prese
Mar 12, 2018 07:30 am ET
InMed to Present at 30th Annual ROTH Capital Conference
VANCOUVER, March 12, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California. InMed'
Mar 06, 2018 03:30 am ET
InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
Publication on a Novel Hydrogel Formulation for the Treatment of Glaucoma Helps Validate InMed's Fully Integrated, Cannabinoid-based Business Model
Mar 06, 2018 03:30 am ET
InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
Publication on a Novel Hydrogel Formulation for the Treatment of Glaucoma Helps Validate InMed's Fully Integrated, Cannabinoid-based Business Model
Mar 02, 2018 06:30 am ET
InMed Receives Conditional Approval to List on the Toronto Stock Exchange
CSE:IN OTCQB:IMLFF
Mar 02, 2018 06:30 am ET
InMed Receives Conditional Approval to List on the Toronto Stock Exchange
CSE:IN OTCQB:IMLFF
Jan 04, 2018 11:29 am ET
IIROC Trade Resumption - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - Trading resumes in:
Jan 04, 2018 11:28 am ET
IIROC Trading Halt - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - The following issues have been halted by IIROC:
Jan 04, 2018 09:08 am ET
IIROC Trade Resumption - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - Trading resumes in:
Jan 04, 2018 09:04 am ET
IIROC Trading Halt - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - The following issues have been halted by IIROC:
Jan 04, 2018 05:00 am ET
InMed Closes Over-Subscribed C$9.4 Million Financing
/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES/
Dec 22, 2017 08:30 am ET
CannabisNewsWire Announces Publication on Increased Investment Activity in Cannabis
New York, New York--(Newsfile Corp. - December 22, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 21, 2017 08:30 am ET
CannabisNewsWire Announces Publication Discussing Biotech's Leading Role in the Cannabis Industry
New York, New York--(Newsfile Corp. - December 21, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 20, 2017 10:17 am ET
IIROC Trade Resumption - IN
VANCOUVER, Dec. 20, 2017 /CNW/ - Trading resumes in:
Dec 20, 2017 08:46 am ET
IIROC Trading Halt - IN
VANCOUVER, Dec. 20, 2017 /CNW/ - The following issues have been halted by IIROC:
Dec 18, 2017 04:15 pm ET
InMed Announces Non-Brokered Private Placement
CSE: INOTCQB: IMLFF
Dec 18, 2017 08:30 am ET
NetworkNewsWire Announces Publication on the Value of Cannabinoid-based Alternatives to Opioids
New York, New York--(Newsfile Corp. - December 18, 2017) - NetworkNewsWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 18, 2017 07:00 am ET
Horizons ETFs Expands the Portfolio of its Marijuana-Focused ETF
Upon quarterly rebalance, 11 stocks were added to the HMMJ portfolio
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
